Prevention of corticosteroid-induced osteoporosis and fractures.
O'Mahony
D
D
Clinical Investigation Unit, Queen Elizabeth Hospital, Birmingham, UK. d.omahony@bham.ac.uk
D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D002116:Calcitonin / Q000627:therapeutic use; D002117:Calcitriol / Q000627:therapeutic use; D002120:Calcium Channel Agonists / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D010880:Piperidines / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride
D000305:Adrenal Cortex Hormones; D002120:Calcium Channel Agonists; D004965:Estrogen Antagonists; D010880:Piperidines; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D002117:Calcitriol